FLT3 and acute myeloid leukemia: Many AML patients show normal karyocytes [36, 37], but they acquire activating de novo mutations that have prognostic relevance and impact on many biological functions, including length mutations or internal tandem duplications of the FLT3 gene (FLT3-ITD) [35, 38, 39] and mutations of transcription factor genes, such as CEBPA, which plays an important role in differentiation [40, 41].